News: Indonesia

The government primarily focuses on developing phytopharmaceuticals to create a system of health resilience and domestic pharmaceutical self-reliance. Launching the Phytopharmaca Formulary and promoting its usage in medical institutions are examples of the government's commitment to fostering the use of phytopharmaceuticals. The Director General of Pharmaceuticals and Medical Devices at…

With more than 28000 plant species and 2,848 medicinal plants, Indonesia has the second-highest biodiversity in the world. Its natural resources hold tremendous promise for developing phytopharmaceuticals and herbal medicines, including Indonesia Indigenous Modern Medicine (IIMM). Penny K. Lukito, head of the Food and Drug Supervisory Agency (BPOM), stated that…

The Indonesian government continues to encourage the resilience and independence of the healthcare industry, as imports dominate 90% of its domestic pharmaceutical raw materials and health spending. In addition, 88% of medical device transactions through electronic catalogs (e-catalogs) are imported products. Meanwhile, research and development funds are only about 0.2%…

Indonesia's 29th National Family Day (Harganas) was celebrated with the theme "Let's Prevent Stunting for Stunting-Free Family". President Joko Widodo (Jokowi) said that the government had appointed the National Population and Family Planning Agency (BKKBN) to reduce the prevalence of stunting to 14% in 2024. Therefore, BKKBN collaborates with several…

The Covid-19 epidemic has given Indonesia's pharmaceutical sector a fresh start. In stark contrast to the average 5–10% growth rate, the pharmaceutical sector shrank by -1.6 percent. Meanwhile, a supply shock made it challenging for the nation to get medical raw materials (BBO) since imports met 90% of BBO requirements.…

Dexa Group received the Outstanding Program in Prioritizing Public Health Needs award from Warta Ekonomi's Indonesia Best CSR Award 2022 for its contribution to the healthcare industry. This honor is granted in recognition of Dexa Group's significant work putting social responsibility and environmental responsibility initiatives into action. On Thursday, June…

Dexa Group participated in the Proudly Made in Indonesia 2022 event once more to accelerate the independence of domestic local products. On Thursday, June 23, 2022, the Bangga Buatan Indonesia (BBI) event with the title Lagawi Fest (Lampung Bangga Wirausaha Industri Festival) Satu Bumi Juta Karya was held on Tegal…

STIMUNO has served as Indonesia's first phytopharmaceutical immunomodulator for over two decades. It also has won several honors since its initial release in 1999. For the 12th year in a row, STIMUNO syrup won the Top Brand For Kids Awards in the Children's Immune System Vitamins category. Marketing Magazine and…

The ‘Bangga Buatan Indonesia’ Movement (BBI) is supported by 35 District/City Health Offices in Central Java Province, which provide the Special Allocation Fund (DAK) and the APBD for health expenditure on Indonesian Indigenous Modern Medicines (OMAI). Thie program is not just to comply with Presidential Instruction (Inpres) No. 2 of…

Dexa Group, was named the Indonesia Most Acclaimed Company (IMACO) 2022 in the Healthcare Industry category for Outstanding Corporate Strategy for Innovative Business by Warta Ekonomi. This award validates Dexa Group's commitment as a national pharmaceutical company to continue innovating via competitive product research and development to achieve pharmaceutical independence.…